However, the revelation of this obesity‐specific mechanism of hepatic toxicity in our study underscores a pivotal new consideration in the pursuit of designing innovative URAT1 inhibitors derived from the structural scaffold of the necessity of ascertaining their potential PPARγ agonistic activities. This evidence concerns the gene SLC22A12 and obesity disorder.